Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Research Article

Loss of Notch1 activity inhibits prostate cancer growth and metastasis and sensitizes prostate cancer cells to anti-androgen therapies

Meghan A. Rice, En-Chi Hsu, Merve Aslan, Ali Ghoochani, Austin Su and Tanya Stoyanova
Meghan A. Rice
Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Meghan A. Rice
En-Chi Hsu
Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for En-Chi Hsu
Merve Aslan
Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Ghoochani
Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Austin Su
Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanya Stoyanova
Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: stanya@stanford.edu
DOI: 10.1158/1535-7163.MCT-18-0804
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Additional Files

  • Supplementary Data

    • Supplementary Figures 1-7 - Supplementary Figure 1. Quantification of immunoblotting in Figure 1. Supplementary Figure 2. Animal weights from Figure 3 xenografts. Supplementary Figure 3. Quantification of immunoblotting from xenograft tissues in Figure 3. Supplementary Figure 4. Viability of GSI combination therapy with anti-androgens Enzalutamide or Abiraterone. Supplementary Figure 5. GSI and anti-Androgen therapies synergize to decrease colony formation of CRPC cells. Supplementary Figure 6. GSIs synergize with anti-androgens Enzalutamide and Abiraterone to inhibit prostate cancer cell migration in vitro. Supplementary Figure 7. Matrigel Dot assay performed on 22RV1 cells was not able to assay migration.
Next
Back to top

Published OnlineFirst April 26, 2019
doi: 10.1158/1535-7163.MCT-18-0804

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Loss of Notch1 activity inhibits prostate cancer growth and metastasis and sensitizes prostate cancer cells to anti-androgen therapies
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
Citation Tools
Loss of Notch1 activity inhibits prostate cancer growth and metastasis and sensitizes prostate cancer cells to anti-androgen therapies
Meghan A. Rice, En-Chi Hsu, Merve Aslan, Ali Ghoochani, Austin Su and Tanya Stoyanova
Mol Cancer Ther April 26 2019 DOI: 10.1158/1535-7163.MCT-18-0804

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Loss of Notch1 activity inhibits prostate cancer growth and metastasis and sensitizes prostate cancer cells to anti-androgen therapies
Meghan A. Rice, En-Chi Hsu, Merve Aslan, Ali Ghoochani, Austin Su and Tanya Stoyanova
Mol Cancer Ther April 26 2019 DOI: 10.1158/1535-7163.MCT-18-0804
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Clinical next generation sequencing in advanced melanoma
  • Mutation interactions in drug response prediction models
  • Eribulin effects on clear cell sarcoma
Show more Research Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement